Podocalyxin-like protein 1 is a relevant marker for human c-kitpos cardiac stem cells

Journal of Tissue Engineering and Regenerative Medicine

Volumn 10, Issue 7, 2016, Pages 580-590

  Moscoso, Isabel ^a   Tejados, Naiara ^b   Barreiro, Olga ^a   Sepúlveda, Pilar ^c   Izarra, Alberto ^a   Calvo, Enrique ^a   Dorronsoro, Akaitz ^b   Salcedo, Juan Manuel ^b   Sádaba, Rafael ^d   Díez Juan, Antonio ^e   Trigueros, César ^b   Bernad, Antonio ^a  

^a CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^b Cell Reprogramming Unit   (Spain)

^c INSTITUTO DE INVESTIGACIÓN SANITARIA DEL HOSPITAL CLÍNICO SAN CARLOS IDISSC   (Spain)

^d Universidad Pública de Navarra   (Spain)

^e CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

Author keywords

differentiation; Human cardiac progenitor cells; immunoregulation; membrane proteome; migration; PODXL

Indexed keywords

ACTIVATION ANALYSIS; CARDIOLOGY; CELL CULTURE; CELL MEMBRANES; COPYRIGHTS; DISEASE CONTROL; HEART; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; STEM CELLS;

CARDIAC PROGENITORS; CARDIAC STEM CELLS; CELL SURFACE MARKER; DIFFERENTIATION; HUMAN CARDIAC PROGENITOR CELL; IMMUNOREGULATION; MEMBRANE PROTEOME; MIGRATION; PODOCALYXIN-LIKE PROTEIN 1; PROGENITOR CELL;

PROTEINS;

CELL MARKER; DIPEPTIDYL PEPTIDASE IV; MYOFERLIN; PODOCALYXIN LIKE PROTEIN 1; PROTEOME; STEM CELL FACTOR; UNCLASSIFIED DRUG; DIFFERENTIATION ANTIGEN; PODOCALYXIN; SIALOGLYCOPROTEIN; STEM CELL FACTOR RECEPTOR;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIAC STEM CELL; CELL ACTIVATION; CELL ADHESION; CELL DIFFERENTIATION; CELL FUNCTION; CELL MIGRATION; CELL SURFACE; CONTROLLED STUDY; DOWN REGULATION; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; IMMUNOREGULATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MESENCHYMAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; RAT; BIOSYNTHESIS; CARDIAC MUSCLE; CYTOLOGY; FEMALE; MALE; MESENCHYMAL STROMA CELL; METABOLISM;

ANTIGENS, DIFFERENTIATION; FEMALE; HUMANS; MALE; MESENCHYMAL STROMAL CELLS; MYOCARDIUM; PROTO-ONCOGENE PROTEINS C-KIT; SIALOGLYCOPROTEINS;

EID: 84880737575     PISSN: 19326254     EISSN: 19327005     Source Type: Journal    
DOI: 10.1002/term.1795     Document Type: Article

References (42)

1. Agarwal N, Lippmann ES, Shusta EV. 2010; Identification and expression profiling of blood-brain barrier membrane proteins. J Neurochem 112: 625–635.
2. Anversa P, Leri A, Rota M et al. 2007; Concise review: stem cells, myocardial regeneration, and methodological artifacts. Stem Cells 25: 589–601.
3. Assmus B, Rolf A, Erbs S et al. 2010; Clinical outcome 2 years after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction. Circ Heart Fail 3: 89–96.
4. Beltrami AP, Barlucchi L, Torella D et al. 2003; Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 114: 763–776.
5. Bergmann O, Bhardwaj RD, Bernard S et al. 2009; Evidence for cardiomyocyte renewal in humans. Science 324: 98–102.
6. Bolli R, Chugh AR, D'Amario D et al. 2011; Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 378: 1847–1857.
7. Cao R, Chen K, Song Q et al. 2012; Quantitative proteomic analysis of membrane proteins involved in astroglial differentiation of neural stem cells by SILAC labeling coupled with LC-MS/MS. J Proteome Res 11: 829–838.
8. Carvalho MM, Teixeira FG, Reis RL et al. 2011; Mesenchymal stem cells in the umbilical cord: phenotypic characterization, secretome and applications in central nervous system regenerative medicine. Curr Stem Cell Res Ther 6: 221–228.
9. + exchanger (NHE1) activation in cardiac myocytes. Cardiovasc Res 81: 294–300.
10. Dawn B, Guo Y, Rezazadeh A et al. 2006; Postinfarct cytokine therapy regenerates cardiac tissue and improves left ventricular function. Circ Res 98: 1098–1105.
11. Demonbreun AR, Posey AD, Heretis K et al. 2010; Myoferlin is required for insulin-like growth factor response and muscle growth. FASEB J 24: 1284–1295.
12. Ellison GM, Torella D, Dellegrottaglie S et al. 2011; Endogenous cardiac stem cell activation by insulin-like growth factor-1/hepatocyte growth factor intracoronary injection fosters survival and regeneration of the infarcted pig heart. J Am Coll Cardiol 58: 977–986.
13. Fernandez D, Larrucea S, Nowakowski A et al. 2011; Release of podocalyxin into the extracellular space. Role of metalloproteinases. Biochim Biophys Acta 1813: 1504–1510.
14. Gyongyosi M, Lang I, Dettke M et al. 2009; Combined delivery approach of bone marrow mononuclear stem cells early and late after myocardial infarction: the MYSTAR prospective, randomized study. Nat Clin Pract Cardiovasc Med 6: 70–81.
15. Hahn AF, Boman H. 1993; Cold-induced sweating syndrome including Crisponi Syndrome. In GeneReviews, Pagon RA, Bird TD, Dolan CR et al. (eds). Seattle, WA: University of Washington, Seattle, 1993–2013.
16. Hosoda T. 2012; C-kit-positive cardiac stem cells and myocardial regeneration. Am J Cardiovasc Dis 2: 58–67.
17. Koch LK, Zhou H, Ellinger J et al. 2008; Stem cell marker expression in small cell lung carcinoma and developing lung tissue. Hum Pathol 39: 1597–1605.
18. Laflamme MA, Murry CE. 2011; Heart regeneration. Nature 473: 326–335.
19. Larrucea S, Butta N, Arias-Salgado EG et al. 2008; Expression of podocalyxin enhances the adherence, migration, and intercellular communication of cells. Exp Cell Res 314: 2004–2015.
20. Lee RH, Seo MJ, Pulin AA et al. 2009a; The CD34-like protein PODXL and alpha6-integrin (CD49f) identify early progenitor MSCs with increased clonogenicity and migration to infarcted heart in mice. Blood 113: 816–826.
21. Lee SK, Kim Y, Kim SS et al. 2009b; Differential expression of cell surface proteins in human bone marrow mesenchymal stem cells cultured with or without basic fibroblast growth factor containing medium. Proteomics 9: 4389–4405.
22. Lee ST, White AJ, Matsushita S et al. 2011; Intramyocardial injection of autologous cardiospheres or cardiosphere-derived cells preserves function and minimizes adverse ventricular remodeling in pigs with heart failure post-myocardial infarction. J Am Coll Cardiol 57: 455–465.
23. Leri A, Kajstura J, Anversa P. 2011; Role of cardiac stem cells in cardiac pathophysiology: a paradigm shift in human myocardial biology. Circ Res 109: 941–961.
24. Malliaras K, Li TS, Luthringer D et al. 2012; Safety and efficacy of allogeneic cell therapy in infarcted rats transplanted with mismatched cardiosphere-derived cells. Circulation 125: 100–112.
25. Martin-Puig S, Wang Z, Chien KR. 2008; Lives of a heart cell: tracing the origins of cardiac progenitors. Cell Stem Cell 2: 320–331.
26. Martinez-Estrada OM, Lettice LA, Essafi A et al. 2010; Wt1 is required for cardiovascular progenitor cell formation through transcriptional control of Snail and E-cadherin. Nat Genet 42: 89–93.
27. Martinez-Sales V, Sanchez-Lazaro I, Vila V et al. 2011; Circulating endothelial cells in patients with heart failure and left ventricular dysfunction. Dis Markers 31: 75–82.
28. Mazo M, Hernández S, Gavira JJ et al. 2012; Treatment of reperfused ischemia with adipose-derived stem cells in a preclinical Swine model of myocardial infarction. Cell Transplant 21: 2723–2733.
29. Meng X, Ezzati P, Wilkins JA. 2011; Requirement of podocalyxin in TGF-beta induced epithelial mesenchymal transition. PLoS One 6: 1–10.
30. Messina E, De Angelis L, Frati G et al. 2004; Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res 95: 911–921.
31. Nauta AJ, Fibbe WE. 2007; Immunomodulatory properties of mesenchymal stromal cells. Blood 110: 3499–3506.
32. Ott HC, Matthiesen TS, Goh SK et al. 2008; Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart. Nat Med 14: 213–221.
33. Posey AD Jr, Pytel P, Gardikiotes K et al. 2011; Endocytic recycling proteins EHD1 and EHD2 interact with fer-1-like-5 (Fer1L5) and mediate myoblast fusion. J Biol Chem 286: 7379–7388.
34. Sarkar P, Collier TS, Randall SM et al. 2012; The subcellular proteome of undifferentiated human embryonic stem cells. Proteomics 12: 421–430.
35. Sathyanarayana P, Menon MP, Bogacheva O et al. 2007; Erythropoietin modulation of podocalyxin and a proposed erythroblast niche. Blood 110: 509–518.
36. Segers VF, Lee RT. 2008; Stem-cell therapy for cardiac disease. Nature 451: 937–942.
37. Stastna M, Chimenti I, Marban E et al. 2010; Identification and functionality of proteomes secreted by rat cardiac stem cells and neonatal cardiomyocytes. Proteomics 10: 245–253.
38. Tan HL, Fong WJ, Lee EH et al. 2009; mAb 84, a cytotoxic antibody that kills undifferentiated human embryonic stem cells via oncosis. Stem Cells 27: 1792–1801.
39. Tsukada S, Iwai M, Nishiu J et al. 2003; Inhibition of experimental intimal thickening in mice lacking a novel G-protein-coupled receptor. Circulation 107: 313–319.
40. Wang D, Li Y, Wu C et al. 2011; PINCH1 is transcriptional regulator in podocytes that interacts with WT1 and represses podocalyxin expression. PLoS One 6: 1–10.
41. Yang L, Nyalwidhe JO, Guo S et al. 2011; Targeted identification of metastasis-associated cell-surface sialoglycoproteins in prostate cancer. Mol Cell Proteomics 10: 1–16.
42. Yu C, Sharma A, Trane A et al. 2011; Myoferlin gene silencing decreases Tie-2 expression in vitro and angiogenesis in vivo. Vascul Pharmacol 55: 26–33.